Physician profile
Anitha Bhat
NPI 1639480585
$1,491.66
in general payments reported to CMS, 2019-2025
22 companies · $255 in 2025
The $255 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.51 · 2020: $145 · 2021: $162 · 2022: $231 · 2023: $283 · 2024: $398 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $912 · Education: $24.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $911.56 |
| Education | $24.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $266.41 | 2021-2025 | Freestyle Libre 3, Aliniq |
| Lilly USA, LLC | $223.93 | 2020-2025 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.23 | 2020-2023 | Jardiance |
| Pfizer INC. | $104.56 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.91 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $93.03 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $82.60 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $61.12 | 2020-2024 | Gardasil, Gardasil 9 |
| Glaxosmithkline, LLC. | $59.44 | 2022-2024 | Trelegy Ellipta, Shingrix |
| Xeris Pharmaceuticals, INC. | $59.03 | 2023-2025 | Gvoke Hypopen, Keveyis |
| Neurocrine Biosciences, INC. | $56.65 | 2023-2024 | Ingrezza |
| Eisai INC. | $33.49 | 2021-2022 | |
| Exact Sciences Corporation | $31.69 | 2024-2025 | Cologuard Collection Kit |
| Philips North America LLC | $31.45 | 2023-2025 | Respiratory |
| Janssen Pharmaceuticals, INC | $31.29 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $25.19 | 2024 | Krystexxa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.59 | 2023 | Rexulti |
| Abbvie INC. | $19.42 | 2021 | |
| Optinose US, INC. | $19.02 | 2020 | |
| Astellas Pharma US INC | $18.95 | 2022 | |
| Circassia INC. | $17.51 | 2019 | |
| Phadia US INC. | $17.15 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anitha Bhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.